Experts at the 2026 Fall Clinical Dermatology Conference review landmark drug approvals, emerging pipelines, and updated ...
Key insights from Fall Clinical 2026 on diagnosing and managing inflammatory skin conditions and post-inflammatory dyspigmentation in patients with skin of color.
Phase 3 HER2CLIMB-05 trial demonstrates a 35.9% reduction in risk of disease progression or death with maintenance tucatinib combination.
Key takeaways from the 26th annual Fall Clinical Dermatology Conference held in Las Vegas, Nevada were published.
Findings seen among pediatric patients presenting to the emergency department with moderate-to-severe acute pain ...
Officials say low vaccination rates in rural communities are fueling the spread of the highly contagious virus.
Nearly 1 in 3 patients with systemic lupus erythematosus (SLE) are taking a supplement–medication combination with potential for an interaction, according to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results